Paul Denny-Gouldson

As biopharma companies rapidly change their focus, they may lack the laboratory space, instrumentation, and the scientific knowledge to support biologics research.

In the face of spiralling R&D costs, currently estimated at $800 million to produce a new drug, the discovery industry is constantly searching for ways to keep expenditure low, increase productivity and meet ever-stricter guidelines imposed by regulatory bodies.